Anastrozole Side Effects and Management

Introduction to Anastrozole Side Effects

The American Society of Clinical Oncology recommends that anastrozole causes several important side effects that directly impact quality of life, with musculoskeletal symptoms and bone loss being the most clinically significant concerns requiring proactive monitoring and management 1

Joint-related symptoms, such as joint stiffness and arthralgias, occur frequently in 25-30% of patients and are a leading cause of treatment discontinuation, according to the American College of Physicians 1, 2
Musculoskeletal pain appears related to the profound estrogen suppression caused by anastrozole, as noted by the National Comprehensive Cancer Network 3

The American College of Radiology notes that anastrozole significantly increases bone loss and fracture risk, which is the most serious quality-of-life threatening side effect, with decreased bone mineral density in both lumbar spine and hip occurring compared to baseline 1
The National Osteoporosis Foundation recommends that increased fracture risk, particularly of spine, hip, and wrist, is a significant concern, with fracture rates being significantly higher than with tamoxifen (7.1% vs 4.1% after 37 months) 1, 2
Severe osteoporosis (T-score <-4 or >2 vertebral fractures) is a relative contraindication to anastrozole use, as stated by the American Academy of Orthopaedic Surgeons 1

The National Institutes of Health recommends baseline bone mineral density measurement before starting treatment, regular calcium and vitamin D supplementation, weight-bearing exercise, and consideration of bisphosphonates or RANKL inhibitors in patients with moderate bone loss 1, 2

The North American Menopause Society notes that hot flashes and night sweats are very common, occurring in both anastrozole and tamoxifen users, though both drugs cause these symptoms, with vasomotor symptoms being significantly increased with anastrozole in the IBIS-II trial 4, 5, 6, 7

The American College of Obstetricians and Gynecologists recommends that vaginal dryness and dry eyes are common complaints that should be discussed before initiating therapy, with dyspareunia (painful intercourse) occurring more frequently with anastrozole than tamoxifen 1, 2, 8

The American Psychiatric Association notes that depression occurs in a significant proportion of patients, with peripheral edema (leg/ankle swelling) also being a common side effect 8

The American Society of Clinical Oncology recommends that before starting anastrozole, patients must understand that the drug only works in truly postmenopausal women, bone protection is mandatory, and joint symptoms are common but may improve with continued use or require switching to alternative endocrine therapy 1, 2

The National Comprehensive Cancer Network recommends that patients taking anastrozole be monitored for arthralgia and myalgia, which occur more frequently with anastrozole compared to tamoxifen 9
The National Comprehensive Cancer Network also notes that anastrozole is associated with increased stroke risk compared to tamoxifen 9
Additionally, the National Comprehensive Cancer Network reports that anastrozole is associated with hypercholesterolemia, which occurs more frequently with anastrozole than tamoxifen 9

The American Heart Association guidelines are not directly mentioned, but the data suggests that anastrozole increases stroke risk compared to tamoxifen, and patients with pre-existing ischemic heart disease should be monitored closely 9
The National Lipid Association guidelines are not directly mentioned, but the data suggests that anastrozole is associated with hypercholesterolemia, which occurs more frequently with anastrozole than tamoxifen 9

The American College of Rheumatology guidelines are not directly mentioned, but the data suggests that arthralgia and myalgia occur more frequently with anastrozole compared to tamoxifen 9
The North American Menopause Society guidelines are not directly mentioned, but the data suggests that vasomotor symptoms, such as hot flashes and night sweats, are significantly increased with anastrozole 9